Izencitinib
Product Specifications
UNSPSC Description
Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted JAK inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis[1].
Target Antigen
JAK
Type
Reference compound
Related Pathways
Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/izencitinib.html
Purity
99.67
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC1=CC(NC2=CC3=C(C=CC=N3)C(N[C@@H]4C[C@@H](CC5)N(CCC#N)[C@@H]5C4)=N2)=NN1
Molecular Weight
402.50
References & Citations
[1]Kevin S Currie, et al. Small-molecule agents for the treatment of inflammatory bowel disease. Bioorg Med Chem Lett. 2019 Aug 15;29(16):2034-2041.|[2]William J Sandborn, et al. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. J Crohns Colitis. 2020 Sep 16;14(9):1202-1213.|[3]D. Beattie, et al. TD-1473, a novel, potent, and orally administered, GI-targeted, pan-Janus kinase (JAK) inhibitor. Journal of Crohn's and Colitis, Volume 10, Issue suppl_1, March 2016, Page S123.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-109148/Izencitinib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-109148/Izencitinib-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
2051918-33-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
